<DOC>
	<DOC>NCT00127881</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to treatment with Targretin速 and one other standard therapy.</brief_summary>
	<brief_title>Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>A biopsy compatible with the diagnosis of MF and sezary syndrome with a CD4 positive phenotype within 6 months of study entry Refractory to or intolerant to at least two prior therapies, one being Targretin速 (or combinations hereof). Signed informed consent Prior treatment with Total Skin Electron Beam (TSEB) therapy within six months Prior treatment with Campath (alemtuzumab) Prior treatment with more than three regimens of single agent chemotherapy Prior treatment with pentostatin within 6 months Treatment within 4 weeks prior to visit 2 with topical Targretin速, skin directed therapies or systemic anticancer therapies, such as, but not limited to: Targretin速 , UVlight therapy, local Electron Beam Therapy (EBT), extracorporal photo chemotherapy, methotrexate, bleomycin, cyclophosphamide, combination chemotherapy, oral retinoids, systemic glucocorticosteroids , carmustine, nitrogen mustard, systemic vitamin A or etretinate Treatment with topical glucocorticosteroids within 2 weeks prior to visit 2 Unwillingness or inability to avoid prolonged exposure to the sun or UV light sufficient to produce a mild erythema or thought by the investigator to likely modify the patient's disease Concurrent or previous malignancies within the past five years except adequately treated in situ carcinoma of the uterine cervix or basal or squamous cell skin carcinoma Significant concurrent, uncontrolled, or active medical condition including, but not limited to renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral or psychiatric disease Known or suspected positive serology for HIV Known or suspected positive serology for hepatitis B or C Patients who are currently participating in any other trials or having received treatment with any experimental agent within 4 weeks prior to visit 1 (screening) Prior treatment with antiCD4 monoclonal antibodies Breast feeding women or women with a positive pregnancy test at Visit 1 Women of childbearing potential not willing to use either hormonal birth control, an intrauterine device or doublebarrier method for the entire study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Refractory or intolerant to Mycosis Fungoides and sezary syndrome</keyword>
	<keyword>Cutaneous T-cell Lymphoma</keyword>
	<keyword>To evaluate the efficacy and safety of zanolimumab in Mycosis Fungoides and sezary syndrome</keyword>
</DOC>